Venous Thromboembolism | Disease Landscape and Forecast | G7 | 2018

Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The availability of non-vitamin K antagonist oral anticoagulants (NOACs) for the treatment and secondary prophylaxis of VTE is addressing the need for more-convenient alternatives to current standards of care, and these agents will drive market growth during the forecast period. However, considerable areas of unmet need exist within the VTE space, such as primary prophylaxis of VTE in acute medically ill patients and management of VTE treatment and risk in cancer patients. The ongoing label expansion program for NOACs and the anticipated launch of new therapies such as IONIS-FXIRx offer potential solutions to these unmet needs.

Questions Answered:

How do the different VTE subpopulations contribute to the overall VTE market landscape? What will be the key drivers and deterrents for the VTE market during the 2017-2027 forecast period?
How will uptake of newer agents in the market impact current market-leading therapies? Which agents will be the most successful and why?
What do thought leaders think of the label expansion programs for NOACs? How do physicians perceive betrixaban, a new NOAC on the market, for managing medically ill patients?
Which patient subpopulations have the greatest unmet need and commercial potential? Which drugs under development will fulfill these unmet needs?

Scope:

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with thought leaders in the field.

Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.

Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.

Emerging therapies: Phase II: 3 drugs; Phase III: 3 drugs. Coverage of select preclinical and P

Contact sales account_box

Venous Thromboembolism US 2018

Report

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

north_east

Report

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

north_east

Report

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

north_east

Report

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

north_east

Product logins

Venous Thromboembolism | Disease Landscape and Forecast | G7 | 2018

Related Market Assessment Reports

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Follow us

Contact us